NILT.OB Insider Trading Activity and SEC Form 4 Filings
NILT.OB insider trading summary
No open-market insider purchases or sales of Nile Therapeutics, Inc. (NILT.OB) have been reported on SEC Form 4 in the past 12 months.
Latest NILT.OB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 15, 2008 | Gregory W Schafer | Director | Buy | $460 (100 @ $4.60) |
| Apr 14, 2008 | Daron Evans | Chief Financial Officer | Buy | $940 (200 @ $4.70) |
| Apr 14, 2008 | Peter M Strumph | Chief Executive Officer | Buy | $940 (200 @ $4.70) |
| Apr 14, 2008 | Daron Evans | Chief Financial Officer | Buy | $900 (200 @ $4.50) |
| Apr 14, 2008 | Peter M Strumph | Chief Executive Officer | Buy | $5K (1,000 @ $4.70) |
| Apr 14, 2008 | Daron Evans | Chief Financial Officer | Buy | $900 (200 @ $4.50) |
| Apr 14, 2008 | Peter M Strumph | Chief Executive Officer | Buy | $940 (200 @ $4.70) |
| Apr 14, 2008 | Daron Evans | Chief Financial Officer | Buy | $900 (200 @ $4.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.